GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » Altman Z2-Score

Azenta (Azenta) Altman Z2-Score : 11.21 (As of Apr. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Azenta Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Azenta has a Altman Z2-Score of 11.21, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Azenta's Altman Z2-Score or its related term are showing as below:

AZTA' s Altman Z2-Score Range Over the Past 10 Years
Min: 0.16   Med: 3.04   Max: 17.79
Current: 11.21

During the past 13 years, Azenta's highest Altman Z2-Score was 17.79. The lowest was 0.16. And the median was 3.04.


Azenta Altman Z2-Score Historical Data

The historical data trend for Azenta's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta Altman Z2-Score Chart

Azenta Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.26 4.22 3.36 15.39 12.11

Azenta Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.48 12.94 12.74 12.11 11.21

Competitive Comparison of Azenta's Altman Z2-Score

For the Medical Instruments & Supplies subindustry, Azenta's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azenta's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Azenta's Altman Z2-Score falls into.



Azenta Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Azenta's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.4062+3.26*0.5755+6.72*-0.0108+1.05*6.4197
=11.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $2,824.3 Mil.
Total Current Assets was $1,382.8 Mil.
Total Current Liabilities was $235.6 Mil.
Retained Earnings was $1,625.3 Mil.
Pre-Tax Income was -15.914 + -5.637 + -3.67 + -5.251 = $-30.5 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.0 Mil.
Total Liabilities was $380.7 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1382.801 - 235.62)/2824.314
=0.4062

X2=Retained Earnings/Total Assets
=1625.285/2824.314
=0.5755

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-30.472 - 0)/2824.314
=-0.0108

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(2443.664 - 0)/380.65
=6.4197

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Azenta has a Altman Z2-Score of 11.21 indicating it is in Safe Zones.


Azenta  (NAS:AZTA) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Azenta Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Azenta's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Azenta (Azenta) Business Description

Traded in Other Exchanges
Address
200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
Executives
Herman Cueto officer: EVP, Chief Financial Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes officer: VP, Chief Accounting Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray officer: Chief Strategy & New Business C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin director
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne officer: SVP and GM, Life Sciences Proj 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou officer: SVP and General Manager, Genom 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus officer: EVP & Chief Operating Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson officer: EVP & Chief Financial Officer C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley officer: Chief Human Resources Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram officer: VP, Finance & Corp. Controller 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De officer: Chief Commercial Officer, LS 15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka officer: Sr. VP, General Manager 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha officer: SVP, GM BLS-Products 15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824